InnoCare Pharma Ltd 09969
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
-
Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024
-
InnoCare Releases 2024 Interim Results and Business Highlights
-
British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents
-
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.11
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.06%
Company Profile
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,109
- Website
- https://www.innocarepharma.com
Comparables
Valuation
|
Metric
|
09969
|
09688
|
IMU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.50 | 3.22 | 2.97 |
Price/Sales | 12.11 | 6.94 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
09969
09688
IMU
Financial Strength
|
Metric
|
09969
|
09688
|
IMU
|
|---|---|---|---|
Quick Ratio | 3.74 | 2.81 | 3.66 |
Current Ratio | 3.82 | 3.46 | 3.86 |
Interest Coverage | −25.88 | — | −321.34 |
Quick Ratio
09969
09688
IMU
Profitability
|
Metric
|
09969
|
09688
|
IMU
|
|---|---|---|---|
Return on Assets (Normalized) | −4.69% | −22.08% | −67.09% |
Return on Equity (Normalized) | −6.63% | −27.96% | −77.26% |
Return on Invested Capital (Normalized) | −7.87% | −31.10% | −79.58% |
Return on Assets
09969
09688
IMU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tclgftxdqk | Wpql | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tzysxljgs | Lntckb | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nywpzncv | Cjzjchp | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mdjdbnwm | Zmlqslw | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Zxsrcgt | Ltrv | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Brbhssrxd | Ytxbp | $28.1 Bil | |||
| Moderna Inc
MRNA
| Qcrzbzk | Whwg | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qnpkxmjzb | Lfpxt | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pbbmcgzr | Mmyqgd | $13.4 Bil | |||
| Incyte Corp
INCY
| Mkxtybmt | Zsxxcj | $12.7 Bil |
United States